| Literature DB >> 27018050 |
Yuka Kobayashi1,2, Kazuhiro Kimura3, Youichiro Fujitsu1, Kuniisa Shinkawa1, Hiroko Muta4, Koh-Hei Sonoda1.
Abstract
PURPOSE: Lymphoproliferative disorders (LPDs) can develop in patients treated with methotrexate (MTX) and usually respond well to MTX withdrawal. Mucosa-associated lymphoid tissue (MALT) lymphoma is a relatively rare type of MTX-LPD. The development of MTX-LPD in the orbit has not been previously described. We here report a case of orbital MALT lymphoma that disappeared after MTX withdrawal in a patient treated with MTX for rheumatoid arthritis. CASE: A 78-year-old woman who complained of swelling of the left upper eyelid had been treated with MTX for >8 years for rheumatoid arthritis. Slit-lamp examination revealed a temporal subconjunctival mass, salmon pink in color, in the left eye. Fundus photographs also suggested the presence of a temporal tumor in the left orbit. [(18)F]Fluorodeoxyglucose positron emission tomography-computed tomography revealed highly integrated lesions in the left inferotemporal orbit and a left external iliac lymph node, a left obturator lymph node, and an inguinal lymph node. Pathologic analysis of a tumor biopsy specimen showed small- and medium-sized lymphocytes positive for CD20, MIB-1, and bcl-2 and negative for CD10, CD3, bcl-1, IgG4, and EBV-ISH. On the basis of these findings, we diagnosed the tumor as MTX-induced MALT lymphoma. The subconjunctival and orbital masses disappeared gradually over 10 months after MTX withdrawal and did not recur within 2 years.Entities:
Keywords: Malignant lymphoma; Methotrexate-associated lymphoproliferative disorder (MTX-LPD); Mucosa-associated lymphoid tissue (MALT) lymphoma; Orbital lymphoma; Rheumatoid arthritis
Mesh:
Substances:
Year: 2016 PMID: 27018050 DOI: 10.1007/s10384-016-0439-z
Source DB: PubMed Journal: Jpn J Ophthalmol ISSN: 0021-5155 Impact factor: 2.447